ClinicalTrials.gg
Active, not recruitingNCT02208362Updated Nov 4, 2026Results posted

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

A Phase 1 interventional study of Arm 1: IL13Ra2-specific CAR Tcm cells and Arm 2: IL13Ra2-specific CAR Tcm cells in Recurrent Glioblastoma, Recurrent Malignant Glioma and Recurrent WHO Grade II Glioma, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Updated Nov 4, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Glioblastoma by City of Hope Medical Center — 6 open to participants now, 12 under way, none of them phase 3. Glioblastoma · City of Hope Medical Center.

Enrollment
Largest of 22
65 · median 19
Started
2015
the only one that year
Phase 1
20 of 23
4 open now
Primary completion
2021-02
later than 0 of 11 live
Registered
12th of 23
by date

Among the 23 studies in Glioblastoma by City of Hope Medical Center, this one has the largest enrollment of the 22 interventional ones that give a count, is the only one that started in 2015, is one of 20 in phase 1, reaches primary completion later than 0 of the 11 other live ones, and was the 12th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

6 of the 23 studies in Glioblastoma by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Glioblastoma by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.

Read the detailed description

PRIMARY OBJECTIVES:

I. Assess the feasibility and safety of cellular immunotherapy utilizing ex vivo expanded autologous memory-enriched T cells (Arms 1, 2, 3, or 4 = Tcm or Arm 5 = Tn/mem) that are genetically modified using a self-inactivating (SIN) lentiviral vector to express an interleukin 13 receptor alpha 2 (IL13Ra2)-specific, hinge-optimized, 41BB-costimulatory chimeric antigen receptor (CAR), as well as a truncated CD19 (CD19t) for participants with recurrent/refractory malignant glioma in one of the following ways: (1) directly into the tumor (intratumoral), (2) into the tumor cavity (intracavitary), (3) into the lateral ventricles (intraventricular), or (4) into both the tumor/tumor cavity (intratumoral) and into the lateral ventricles (intraventricular) (dual delivery).

II. Determine maximum tolerated dose schedule (MTD)/maximum feasible dose schedule (MFD) and a recommended phase II dosing plan (RP2D) for each arm based on dose limiting toxicities (DLTs) and the full toxicity profile.

SECONDARY OBJECTIVES:

I. In research participants who receive the full schedule of three CAR+ T cell doses:

  • Estimate disease response rates,
  • Estimate median overall survival, and
  • Estimate the mean change from baseline in quality of life using the EORTC QLQ-C30 during and post treatment;

II. Describe cytokine levels (tumor cavity fluid, CSF, peripheral blood) over the study period.

III. Describe CAR T cell and endogenous immune populations (CSF, tumor cavity fluid, peripheral blood) over the study period; and IV. Identify tumor and tumor micro-environment markers associated with response to CAR T cells.

EXPLORATORY OBJECTIVES:

I. Assess the timing and extent of brain inflammation following CAR T cell administration; II. Evaluate CAR T cell product characteristics; and

III. For research participants who undergo a second resection or autopsy:

  • Evaluate CAR T cell persistence in the tumor micro-environment and the location of the CAR T cells with respect to the injection, and
  • Evaluate IL13Rα2 antigen expression levels pre and post CAR T cell therapy.

OUTLINE: This is a dose-escalation study. Research subjects will receive an initial low dose (cycle 1) followed by 2 additional infusions at a higher cell dose (cycles 2 and 3) of autologous IL13Ra2-CAR/CD19t+ Tcm or Tn/mem, potentially followed by additional cycles at up to the highest tolerated cell dose (cycles 4+). CAR T cells will be administered in one of four ways:

ARM 1: (Intratumoral delivery a/f biopsy): Patients receive IL13Ra2-CAR/CD19t+ Tcm directly into the tumor via intratumoral (ICTb) catheter. Patients who progress on intratumoral administration may move to intraventricular catheter for the optional infusions.

ARM 2: (Intratumoral delivery a/f biopsy/Intracavitary a/f resection): Patients receive IL13Ra2-CAR/CD19t+ Tcm directly into the tumor via intratumoral (ICTb) catheter, or into the tumor resection cavity via intracavitary (ICTr) catheter. Patients who progress on intratumoral/intracavitary administration may move to intraventricular catheter for the optional infusions.

ARM 3: (Intraventricular delivery): Patients receive IL13Ra2-CAR/CD19t+ Tcm via intraventricular (ICV) catheter.

ARM 4: (Dual delivery): Patients receive IL13Ra2-CAR/CD19t+ Tcm via ICTb/r catheter and ICV catheter. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).

ARM 5: (Dual delivery): Patients receive IL13Ra2-CAR/CD19t+ Tn/mem via ICTb/r catheter and ICV catheter. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).

CAR T cells will be administered at one of three dose schedules:

  • Dose Schedule 1: Cycle 1 - 2x106 CAR T cells, Cycle 2 \& 3 - 10x106 CAR T cells, Total dose - 22x106 CAR T cells; Optional cycles ≤10x106 CAR T cells
  • Dose Schedule 2: Cycle 1 - 10x106 CAR T cells, Cycle 2 \& 3 - 50x106 CAR T cells, Total dose - 110x106 CAR T cells; Optional cycles ≤50x106 CAR T cells
  • Dose Schedule 3: Cycle 1 - 20x106 CAR T cells, Cycle 2 \& 3 - 100x106 CAR T cells, Total dose - 220x106 CAR T cells; Optional cycles ≤100x106 CAR T cells

After completion of the study treatment, patients are followed up at 4 weeks, 3, 6, 8, 10, and 12 months, and then yearly for 15 years.

03

Conditions studied

  • Recurrent Glioblastoma
  • Recurrent Malignant Glioma
  • Recurrent WHO Grade II Glioma
  • Recurrent WHO Grade III Glioma
  • Refractory Glioblastoma
  • Refractory Malignant Glioma
  • Refractory WHO Grade II Glioma
  • Refractory WHO Grade III Glioma
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SCREENING INCLUSION CRITERIA
  • Participant has a prior -confirmed diagnosis of a grade III or IV glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now has radiographic progression consistent with a grade III or IV malignant glioma (MG) after completing standard therapy
  • Radiographic evidence of progression/recurrence of the more than 12 weeks after the end of the initial radiation therapy
  • performance status (KPS) >= 60%
  • > 4 weeks
  • Women of and men must agree to use adequate (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
  • City of Hope (COH) Clinical Pathology confirms IL13R alpha 2+ tumor expression by immunohistochemistry (>= 20%, 1+)
  • All research participants must have the ability to understand and the willingness to sign a written
  • ELIGIBILITY TO PROCEED WITH PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC) COLLECTION
  • Research participant must not require more than 2 mg three times daily (TID) of dexamethasone on the day of PBMC collection.
  • Research participant must have appropriate venous access
  • At least 2 weeks must have elapsed since the research participant received his/her last dose of prior chemotherapy or radiation
  • ELIGIBILITY TO PROCEED WITH RICKHAM PLACEMENT
  • Creatinine \< 1.6 mg/dL
  • White blood cell (WBC) > 2,000/dl or
  • (ANC) > 1,000
  • >= 100,000/dl
  • (INR) \< 1.3
  • \< 1.5 mg/dL
  • (ALT) and aspartate aminotransferase (AST) \< 2.5 x
  • An interval of at least 12 weeks must have elapsed since the completion of initial radiation therapy
  • Wash-out requirements (standard or ):

    • At least 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen
    • At least 23 days since the completion of Temodar and/or 4 weeks for any other non-nitrosourea-containing cytotoxic chemotherapy regimen; if a patient's most recent treatment was with a targeted agent only, and s/he has recovered from any toxicity of this targeted agent, then a waiting period of only 2 weeks is needed from the last dose and the start of study treatment, with the exception of bevacizumab where a wash out period of at least 4 weeks is required before starting study treatment
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH CAR T CELL INFUSION
  • Research participant has a released cryopreserved T cell product
  • Research participant does not require supplemental oxygen to keep saturation greater than 95% and/or does not have presence of any radiographic abnormalities on chest x-ray that are progressive
  • Research participant does not require pressor support and/or does not have symptomatic cardiac arrhythmias
  • Research participant does not have a fever exceeding 38.5° Celsius (C); there is an absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to T cell infusion and/or there aren't any indications of meningitis
  • Research participant serum total bilirubin does not exceed 2 x normal limit
  • Research participant transaminases does not exceed 2 x normal limit
  • Research participant serum creatinine =\< 1.8 mg/dL
  • Research participant does not have uncontrolled seizure activity following surgery prior to starting the first T cell dose
  • Research participant platelet count must be >= 100,000; however, if platelet level is between 75,000-99,000, then T-cell infusion may proceed after platelet transfusion is given and the post transfusion platelet count is >= 100,000
  • Research participants must not require more than 2 mg TID of dexamethasone during T cell therapy

Exclusion criteria

Exclusion Criteria:

  • SCREENING EXCLUSION CRITERIA
  • Research participant requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks
  • Research participant requires pressor support and/or has symptomatic cardiac arrhythmias
  • Research participant requires dialysis
  • Research participant has uncontrolled seizure activity and/or clinically evident progressive encephalopathy
  • Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study; a legal guardian may substitute for the research participant
  • Research participants with any non-malignant intercurrent illness which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the research participant on protocol shall be ineligible
  • Research participants with any other active
  • Research participants being treated for severe infection or who are recovering from major surgery are ineligible until recovery is deemed complete by the investigator
  • Research participants with any uncontrolled illness including ongoing or active infection; research participants with known active or C infection; research participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections
  • Research participants who have confirmed (HIV) within 4 weeks of screening
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Arm 1 (Tcm-derived CAR T cells, Intratumoral a/f biopsy [ICTb])

    Arm 1 (Tcm-derived CAR T cells, Intratumoral a/f biopsy \[ICTb\]

    Biological: Arm 1: IL13Ra2-specific CAR Tcm cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment

  • Experimental
    Arm 2 (Tcm-derived CAR T cells, ICTb/r)

    Arm 2 (Tcm-derived CAR T cells, Intratumoral a/f biopsy \[ICTb\] or Intracavitary a/f resection \[ICTr\])

    Biological: Arm 2: IL13Ra2-specific CAR Tcm cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment

  • Experimental
    Arm 3 (Tcm-derived CAR T cells, Intraventricular [ICV])

    Arm 3 (Tcm-derived CAR T cells, Intraventricular \[ICV\])

    Biological: Arm 3: IL13Ra2-specific CAR Tcm cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment

  • Experimental
    Arm 4 (Tcm-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)

    Arm 4 (Tcm-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)

    Biological: Arm 4: IL13Ra2-specific CAR Tcm cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment

  • Experimental
    Arm 5 (Tn/mem-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)

    Arm 5 (Tn/mem-derived CAR T cells, Dual delivery: both ICTb/r AND ICV)

    Biological: Arm 5: IL13Ra2-specific CAR Tn/mem cells · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Magnetic Resonance Spectroscopic Imaging · Other: Quality-of-Life Assessment

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 3 or Higher Toxicity Related to CAR T Cells

    Grade 3 or higher toxicity profile for adverse events probably or definitely related to CAR T cells as assessed by the NCI CTCAE version 4.0.

    Time frame: An average of 11 months

  2. Number of Participants Experiencing a Dose Limiting Toxicity (DLT)

    Toxicities will be graded using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT is defined as events attributable to T-cell infusion (probable or definite) with a few expected events that resolve within a specified time and occurring from the time of initial CAR T cell infusion through 1 week following the last infusion cycle (not including optional cycles) unless otherwise specified in this definition: 1. Two grade 3 toxicities at the same dose with the exception of those grade 3 toxicities listed below. 2. Any grade 3 Cytokine release syndrome (CRS) toxicity lasting more than 72 hours without intervention 3. Any grade 3 or higher allergic reaction 4. Any grade 3 or higher autoimmune reaction 5. Any grade 4 toxicity

    Time frame: Up to 1 week following the last course, up to a total of 4 weeks (not including optional courses 4-6)

Secondary outcomes

  1. Number of Participants With Active Response Determined by Response Assessment in Neuro-Oncology (RANO) Criteria

    Counts of active response and progression determined by RANO. Participants achieving stable disease (SD), partial remission (PR), or complete remission (CR) are counted as active. RANO: Complete Response (CR): Disappearance of all enhancing disease sustained for 4 weeks, stable or improved FLAIR/T2 lesions, no new lesions, off corticosteroids and neurologically stable or improved. Partial Response (PR): At least a 50% decrease of all measurable enhancing lesions sustained for 4 weeks, no progression of non-measurable disease, stable or improved FLAIR/T2 lesions, no new lesions, corticosteroids dose stable or reduced and neurologically stable or improved. Stable Disease (SD): Does not qualify for CR, PR or PD, stable FLAIR/T2 lesions, stable or reduced corticosteroids, clinically stable Progressive Disease (PD): At least a 25% increase in enhancing lesions despite stable or increasing steroid dose, increase in FLAIR/T2 lesions, any new lesions, clinical deteriorations.

    Time frame: Between 4 and 8 weeks post 1st CAR T infusion

  2. Number of Participants Alive at 6 Months

    Participants were assessed for vital status up to 6 months post surgery.

    Time frame: From surgery to death from any cause or six months, whichever occurred first

07

Results

Posted Oct 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneArm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3
Started24410335483811
Completed23410334353711
Not completed010000113010
Withdrew: Participant did not complete treatment010000112010
Withdrew: Participant received disallowed treatment000000001000

Outcome measures

PrimaryNumber of Participants With Grade 3 or Higher Toxicity Related to CAR T Cells

Grade 3 or higher toxicity profile for adverse events probably or definitely related to CAR T cells as assessed by the NCI CTCAE version 4.0.

Time frame:
An average of 11 months
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher Toxicity Related to CAR T Cells
ParticipantsArm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3
Encephalopathy — Yes000000010000
Encephalopathy — No24410335383811
Ataxia — Yes000000000001
Ataxia — No24410335483810
PrimaryNumber of Participants Experiencing a Dose Limiting Toxicity (DLT)

Toxicities will be graded using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT is defined as events attributable to T-cell infusion (probable or definite) with a few expected events that resolve within a specified time and occurring from the time of initial CAR T cell infusion through 1 week following the last infusion cycle (not including optional cycles) unless otherwise specified in this definition: 1. Two grade 3 toxicities at the same dose with the exception of those grade 3 toxicities listed below. 2. Any grade 3 Cytokine release syndrome (CRS) toxicity lasting more than 72 hours without intervention 3. Any grade 3 or higher allergic reaction 4. Any grade 3 or higher autoimmune reaction 5. Any grade 4 toxicity

Time frame:
Up to 1 week following the last course, up to a total of 4 weeks (not including optional courses 4-6)
Reported as:
Count of participants · Participants
Number of Participants Experiencing a Dose Limiting Toxicity (DLT)
ParticipantsArm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3
Number of Participants Experiencing a Dose Limiting Toxicity (DLT)000000000000
SecondaryNumber of Participants With Active Response Determined by Response Assessment in Neuro-Oncology (RANO) Criteria

Counts of active response and progression determined by RANO. Participants achieving stable disease (SD), partial remission (PR), or complete remission (CR) are counted as active. RANO: Complete Response (CR): Disappearance of all enhancing disease sustained for 4 weeks, stable or improved FLAIR/T2 lesions, no new lesions, off corticosteroids and neurologically stable or improved. Partial Response (PR): At least a 50% decrease of all measurable enhancing lesions sustained for 4 weeks, no progression of non-measurable disease, stable or improved FLAIR/T2 lesions, no new lesions, corticosteroids dose stable or reduced and neurologically stable or improved. Stable Disease (SD): Does not qualify for CR, PR or PD, stable FLAIR/T2 lesions, stable or reduced corticosteroids, clinically stable Progressive Disease (PD): At least a 25% increase in enhancing lesions despite stable or increasing steroid dose, increase in FLAIR/T2 lesions, any new lesions, clinical deteriorations.

Time frame:
Between 4 and 8 weeks post 1st CAR T infusion
Reported as:
Count of participants · Participants
Number of Participants With Active Response Determined by Response Assessment in Neuro-Oncology (RANO) Criteria
ParticipantsArm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3
Active023512212038
Progression211521223343
SecondaryNumber of Participants Alive at 6 Months

Participants were assessed for vital status up to 6 months post surgery.

Time frame:
From surgery to death from any cause or six months, whichever occurred first
Reported as:
Count of participants · Participants
Number of Participants Alive at 6 Months
ParticipantsArm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3
Number of Participants Alive at 6 Months122623312258

Adverse events

Collected over While on study, an average of 11 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 Dose Schedule 12/2 (100%)0/2 (0%)2/2 (100%)
Arm 2 Dose Schedule 14/4 (100%)1/4 (25%)4/4 (100%)
Arm 2 Dose Schedule 24/4 (100%)2/4 (50%)4/4 (100%)
Arm 2 Dose Schedule 310/10 (100%)2/10 (20%)10/10 (100%)
Arm 3 Dose Schedule 13/3 (100%)3/3 (100%)3/3 (100%)
Arm 3 Dose Schedule 22/3 (66.7%)0/3 (0%)3/3 (100%)
Arm 3 Dose Schedule 34/5 (80%)3/5 (60%)5/5 (100%)
Arm 4 Dose Schedule 14/4 (100%)3/4 (75%)4/4 (100%)
Arm 4 Dose Schedule 27/8 (87.5%)4/8 (50%)8/8 (100%)
Arm 5 Dose Schedule 13/3 (100%)2/3 (66.7%)3/3 (100%)
Arm 5 Dose Schedule 25/8 (62.5%)5/8 (62.5%)8/8 (100%)
Arm 5 Dose Schedule 311/11 (100%)5/11 (45.5%)11/11 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventArm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3
Catheter related infectionInfections and infestations0/20/42/40/100/30/30/50/40/81/30/81/11
Death NOSGeneral disorders0/20/40/41/100/30/31/50/41/80/33/80/11
FeverGeneral disorders0/20/40/40/100/30/30/50/40/81/30/80/11
Lung infectionInfections and infestations0/20/40/40/101/30/30/50/40/80/30/80/11
Wound dehiscenceInjury, poisoning and procedural complications0/20/40/40/101/30/30/50/40/80/30/80/11
HeadacheNervous system disorders0/20/40/40/100/30/30/50/41/81/30/80/11
HydrocephalusNervous system disorders0/20/40/40/101/30/30/50/41/80/31/80/11
SeizureNervous system disorders0/20/40/40/101/30/30/50/40/80/31/80/11
Thromboembolic eventVascular disorders0/20/40/42/101/30/30/50/40/80/31/81/11
SepsisInfections and infestations0/20/40/40/100/30/30/51/40/80/30/80/11
Most frequent other events
Showing 10 of 301
Most frequent other events
EventArm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3
AnemiaBlood and lymphatic system disorders2/23/43/45/103/33/34/52/45/82/36/88/11
Sinus bradycardiaCardiac disorders2/21/43/45/102/33/33/54/44/81/33/86/11
Sinus tachycardiaCardiac disorders1/21/43/47/102/32/33/52/45/83/34/88/11
NauseaGastrointestinal disorders0/21/42/42/101/31/31/53/44/83/35/88/11
VomitingGastrointestinal disorders0/20/42/42/101/31/32/52/44/83/32/87/11
ChillsGeneral disorders0/21/42/47/100/33/33/52/43/82/34/88/11
FatigueGeneral disorders2/24/44/49/103/33/34/54/48/83/37/810/11
FeverGeneral disorders1/21/42/45/102/33/33/51/42/82/34/85/11
PainGeneral disorders2/20/40/42/103/32/30/51/42/82/33/81/11
Lymphocyte count decreasedInvestigations0/24/41/43/103/30/32/53/44/82/35/83/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3Total
Median52.5 (40 to 65)56 (38 to 67)55.5 (41 to 70)44 (32 to 71)56 (44 to 60)49 (42 to 57)56 (16 to 69)59.5 (54 to 65)53 (30 to 65)32 (32 to 35)49 (34 to 56)48 (25 to 65)49 (16 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3Total
Female13031012324525
Male11472342514640
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3Total
Hispanic or Latino11020000103311
Not Hispanic or Latino13483354734651
Unknown or Not Reported0000000000123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3Total
American Indian or Alaska Native0000000000000
Asian0000000111115
Native Hawaiian or Other Pacific Islander0000000000000
Black or African American0010000000001
White243103353626855
More than one race0000000000000
Unknown or Not Reported0000000010124
Region of Enrollment
Region of Enrollment(participants)Arm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3Total
United States2441033548381165
Histology
Histology(Participants)Arm 1 Dose Schedule 1Arm 2 Dose Schedule 1Arm 2 Dose Schedule 2Arm 2 Dose Schedule 3Arm 3 Dose Schedule 1Arm 3 Dose Schedule 2Arm 3 Dose Schedule 3Arm 4 Dose Schedule 1Arm 4 Dose Schedule 2Arm 5 Dose Schedule 1Arm 5 Dose Schedule 2Arm 5 Dose Schedule 3Total
Grade 4 glioblastoma IDH wildtype233632246151047
Grade 4 diffuse midline glioma, H3 K27-altered0000001010002
Grade 3 astrocytoma, IDH mutant0000000011002
Grade 3 oligodendroglioma, IDH-mutant and 1p/19q-codeleted0000001000203
Grade 3 supratentorial ependymoma, NEC0001000000102
Grade 4 diffuse astrocytoma, NOS0010001000002
Grade 4 astrocytoma, IDH mutant0103010001017
08

Study locations

1 site
09

References and documents

Publications

  • Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, Ostberg JR, Aguilar B, Wagner JR, Paul JA, Starr R, Wong RA, Chen W, Shulkin N, Aftabizadeh M, Filippov A, Chaudhry A, Ressler JA, Kilpatrick J, Myers-McNamara P, Chen M, Wang LD, Rockne RC, Georges J, Portnow J, Barish ME, D'Apuzzo M, Banovich NE, Forman SJ, Badie B. Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024 Apr;30(4):1001-1012. doi: 10.1038/s41591-024-02875-1. Epub 2024 Mar 7. PubMed 38454126 ↗
  • Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497. PubMed 28029927 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Feb 2021, 68 months.

Results were first posted in Oct 2024, 3 years 8 months after primary completion.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's 68 months is above that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

Start moved once since we started tracking on Sep 25, 2026: May 2015 → Jun 2015, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2014
First posted
Aug 5, 2014
StartActual
Jun 3, 2015was May 2015
Primary completionActual
Feb 8, 2021
CompletionEst.
May 10, 2027
Results first posted
Oct 30, 2024
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 18, 2015→Jun 3, 2015
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date May 18, 2015→Jun 3, 2015
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02208362
Collaborators
National Cancer Institute (NCI), Food and Drug Administration (FDA)
Responsible party
Sponsor
First posted
Aug 5, 2014
Start date
Jun 3, 2015
Primary completion
Feb 8, 2021
Completion
May 10, 2027 (estimated)
Results posted
Oct 30, 2024
Last update
Nov 4, 2026

Study contacts

Behnam Badie
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

Start the discussion